Alnylam Pharmaceuticals, Inc. (ALNY)

Last Closing Price: 323.59 (2026-03-09)

Net Income (Annual)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Alnylam Pharmaceuticals, Inc. (ALNY) had Net Income of $313.75M for the most recently reported fiscal year, ending 2025-12-31.

Figures for fiscal year ending 2025-12-31
Income Statement Financials
$3.71B
Net Income
$313.75M
$681.87M
$3.03B
$3.21B
$501.58M
$-178.43M
$323.15M
$323.15M
$313.75M
$313.75M
$313.75M
$313.75M
$501.58M
$557.24M
131.00M
134.68M
$2.39
$2.33
Balance Sheet Financials
$4.05B
$513.15M
$915.67M
$4.97B
$1.47B
$1.01B
$2.71B
$4.18B
$789.18M
$789.18M
$789.18M
132.38M
Cash Flow Statement Financials
$524.08M
$436.33M
$-305.19M
$968.65M
$1.66B
$690.15M
$348.24M
--
--
Fundamental Metrics & Ratios
2.76
--
--
0.56
1.28
81.64%
13.51%
13.51%
15.00%
8.70%
8.45%
$465.38M
--
--
--
0.75
8.24
4.78
76.42
39.76%
39.76%
6.32%
17.46%
$5.96
$3.46
$3.89